RCUS 12.21 ▲ 5.62% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Arcus Biosciences Inc.

    NYSE: RCUS · Real-Time Price · USD
    12.21
    0.65 (5.62%)
    At close: Sep 05, 2025, 3:59 PM
    11.94
    -2.25%
    After-hours: Sep 05, 2025, 07:23 PM EDT
    5.62%
    Bid 11.65
    Market Cap 1.3B
    Revenue (ttm) 262M
    Net Income (ttm) -306M
    EPS (ttm) -3.14
    PE Ratio (ttm) -3.89
    Forward PE -2.76
    Analyst Buy
    Ask 12.3
    Volume 929,687
    Avg. Volume (20D) 876,745
    Open 11.74
    Previous Close 11.56
    Day's Range 11.53 - 12.24
    52-Week Range 6.50 - 18.98
    Beta 0.89

    About RCUS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol RCUS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for RCUS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Arcus Biosciences Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    4 months ago
    -1.35%
    Arcus Biosciences shares are trading lower after t... Unlock content with Pro Subscription
    6 months ago
    -16.34%
    Arcus Biosciences shares are trading lower after the company announced a $150 million stock offering.
    news image

    3 days ago · seekingalpha.com

    Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript

    Arcus Biosciences, Inc. (NYSE:RCUS ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Terry Rosen - Co-Founder, Chairman & CEO Jennifer Jarrett - Chief Op...

    news image

    2 weeks ago · businesswire.com

    Arcus Biosciences to Participate in Three Upcoming Investor Conferences

    HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient...

    news image

    3 weeks ago · benzinga.com

    Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

    On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Uranium Energy Corp. UEC, saying, “I like nuclear.”

    news image

    3 weeks ago · seekingalpha.com

    Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

    Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with ...

    news image

    1 month ago · fool.com

    Arcus (RCUS) Q2 Revenue Jumps 310%

    Arcus (RCUS) Q2 Revenue Jumps 310%

    news image

    1 month ago · zacks.com

    Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

    Arcus Biosciences, Inc. (RCUS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.02 per share a year ago.

    news image

    1 month ago · businesswire.com

    Arcus Biosciences Announces New Employment Inducement Grants

    HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

    news image

    1 month ago · businesswire.com

    Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

    HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...

    news image

    2 months ago · https://www.defenseworld.net

    UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,872 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

    UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Arcus Biosciences, Inc. (NYSE:RCUS – Free Report) by 11.3% during the 4th quarter, according to the...

    Add to Watchlist